Literature DB >> 11786045

Targeted retrograde gene delivery for neuronal protection.

Brian K Kaspar1, Dawn Erickson, David Schaffer, Linda Hinh, Fred H Gage, Daniel A Peterson.   

Abstract

The cellular heterogeneity and complex circuitry of the central nervous system make it difficult to achieve precise delivery of experimental and therapeutic agents. We report here an in vivo retrograde gene delivery strategy to target mature projection neurons using adeno-associated virus, a vector with low toxicity and the capacity for long-term gene expression. Viral delivery to axon terminal fields in the hippocampus and striatum resulted in viral internalization, retrograde transport, and transgene expression in specific projection neurons in entorhinal cortex and substantia nigra. Retrograde delivery of the anti-apoptotic gene Bcl2l (also known as Bcl-xL) protected entorhinal projection neurons from subsequent damage-induced cell death. Given the broad distribution of neurons affected by neurodegenerative diseases, gene delivery to both the terminal fields and the projection neurons through retrograde infection provides for strategic therapeutic intervention at both levels of the neural circuit. This approach may also facilitate experimental studies of defined neural circuits.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11786045     DOI: 10.1006/mthe.2001.0520

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  48 in total

1.  Projections of preBötzinger complex neurons in adult rats.

Authors:  Wenbin Tan; Silvia Pagliardini; Paul Yang; Wiktor A Janczewski; Jack L Feldman
Journal:  J Comp Neurol       Date:  2010-05-15       Impact factor: 3.215

2.  Correction of brain oligodendrocytes by AAVrh.10 intracerebral gene therapy in metachromatic leukodystrophy mice.

Authors:  Françoise Piguet; Dolan Sondhi; Monique Piraud; Françoise Fouquet; Neil R Hackett; Ornella Ahouansou; Marie-Thérèse Vanier; Ivan Bieche; Patrick Aubourg; Ronald G Crystal; Nathalie Cartier; Caroline Sevin
Journal:  Hum Gene Ther       Date:  2012-07-23       Impact factor: 5.695

3.  Adeno-associated viral-mediated insulin-like growth factor delivery protects motor neurons in vitro.

Authors:  Andrea M Vincent; Eva L Feldman; Debbie K Song; Verena Jung; Andreas Schild; Wei Zhang; Michael J Imperiale; Nicholas M Boulis
Journal:  Neuromolecular Med       Date:  2004       Impact factor: 3.843

4.  Gene transfer demonstrates that muscle is not a primary target for non-cell-autonomous toxicity in familial amyotrophic lateral sclerosis.

Authors:  Timothy M Miller; Soo H Kim; Koji Yamanaka; Mark Hester; Priya Umapathi; Hannah Arnson; Liza Rizo; Jerry R Mendell; Fred H Gage; Don W Cleveland; Brian K Kaspar
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-12       Impact factor: 11.205

5.  Efficient neuronal gene transfer with AAV8 leads to neurotoxic levels of tau or green fluorescent proteins.

Authors:  Ronald L Klein; Robert D Dayton; Nancy J Leidenheimer; Karen Jansen; Todd E Golde; Richard M Zweig
Journal:  Mol Ther       Date:  2005-12-01       Impact factor: 11.454

Review 6.  Molecular engineering of viral gene delivery vehicles.

Authors:  David V Schaffer; James T Koerber; Kwang-il Lim
Journal:  Annu Rev Biomed Eng       Date:  2008       Impact factor: 9.590

7.  Transgene expression in target-defined neuron populations mediated by retrograde infection with adeno-associated viral vectors.

Authors:  Markus Rothermel; Daniela Brunert; Christine Zabawa; Marta Díaz-Quesada; Matt Wachowiak
Journal:  J Neurosci       Date:  2013-09-18       Impact factor: 6.167

8.  The "perivascular pump" driven by arterial pulsation is a powerful mechanism for the distribution of therapeutic molecules within the brain.

Authors:  Piotr Hadaczek; Yoji Yamashita; Hanna Mirek; Laszlo Tamas; Martha C Bohn; Charles Noble; John W Park; Krystof Bankiewicz
Journal:  Mol Ther       Date:  2006-05-02       Impact factor: 11.454

9.  Transduction of nonhuman primate brain with adeno-associated virus serotype 1: vector trafficking and immune response.

Authors:  Piotr Hadaczek; John Forsayeth; Hanna Mirek; Keith Munson; John Bringas; Phil Pivirotto; Jodi L McBride; Beverly L Davidson; Krystof S Bankiewicz
Journal:  Hum Gene Ther       Date:  2009-03       Impact factor: 5.695

10.  AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease.

Authors:  Nicholas R Franich; Helen L Fitzsimons; Dahna M Fong; Matthias Klugmann; Matthew J During; Deborah Young
Journal:  Mol Ther       Date:  2008-03-25       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.